Leah Kuntz

Psychiatric Times' Editor in Chief shared some insights and data on the psychiatric impacts of COVID-19, and what we might expect in the future.

Modifications to the Clozapine Risk Evaluation and Mitigation Strategy go into effect November 15, 2021. Are you up to date?

Caplyta shows promise as a monotherapy for patients with bipolar I or bipolar II disorder experiencing a major depressive episode

The Chief Medical Officer for the American Foundation for Suicide Prevention sat down to talk with Psychiatric Times about a number of important topics in suicide.

According to German researchers, YouTube and other online platforms could induce a “mass social media-induced illness.”

The American Medical Association is urging policymakers to act now to prevent further opioid overdose deaths.

A vaccine that prevents oxycodone from entering the brain? This might be the safe, long-lasting, cost-effective solution for opioid use disorders.

A recent survey found 70% of Afghanistan veterans have struggled with their mental health since serving.

The FDA is holding a workshop to discuss mandatory opioid prescriber education through the Opioid Analgesic Risk Evaluation and Mitigation Strategy.

The first and only treatment to use proprietary precision olfactory delivery technology to deliver DHE to the upper nasal cavity just received FDA approval.

6 frontline physician groups expressed their concern about the Texas state law that bans abortions after 6 weeks of pregnancy.

The one-of-its-kind 6-month paliperidone palmitate treatment for schizophrenia has received FDA approval.

According to the CDC, construction workers commit suicide 4 times more than the general population. What can be done to stem this hazard?

Mental health care for US service members, refugees, and Afghans will be crucial.

What toll does trauma take on police officers, firefighters, and EMT workers?

First of its kind study found aggression in US couples saw a 6- to 8-fold increase during the pandemic.

The National Correctional Health Care Conference is back and ready to deliver the latest on correctional and public health.

A kappa-opioid receptor with psychedelic effects, this potential agent for treatment-resistant depression and other disorders will be paired with a digital therapeutic for maximum efficacy.

This hypersomnia treatment just received an extended approval for cataplexy and excessive daytime sleepiness.

A new study finds amyloid plaques accelerate the breakup of neurotransmitters, worsening neurodegenerative diseases like Alzheimer disease.

The documentary Orchestrating Change has won the 2021 Austen Riggs Erikson Prize for Excellence in Mental Health Media.

More potential good news for treating Alzheimer disease, as an 18-month open-label extension for lecanemab allows for its breakthrough status.

An extended release, ultra-long acting antipsychotic takes another step forward in the approval process.

After the largest increase in overdose deaths in 50 years, the American Psychiatric Association sends out the call for improved substance use care.

If approved, SLS-002 would be only the second approved product for ASIB.

New research may help better understand psychosis etiology as well as provide potential biomarkers for psychosis.

Novel digital therapy modia will be evaluated in combination with sublingual buprenorphine/naloxone background therapy to see whether it is superior in reducing opioid use.

To combat drug overdoses, the Rhode Island governor signed a bill allowing people to consume pre-obtained drugs under safe, professional supervision of trained staff.

Following criticism for its wide-labeled June approval, the FDA has decided to narrow the patient recommendation for aducanumab.

Donanemab for the treatment of Alzheimer disease has received Breakthrough Therapy designation from the FDA.